

Efficient anticoagulant testing worldwide



## Go-DOAC™

Rapid DOAC measurement test  
with high sensitivity

For research use only. Not for use in diagnostic procedures.

ML-00-01280 Rev01




## Go-DOAC™

DOAC measurement test with high sensitivity

- High sensitivity for all new DOACs (including dabigatran, apixaban, rivaroxaban and edoxaban)
- Resistant to heparin / low factor VIII levels
- Freeze-dried
- Stability: 1 years (after reconstitution) at 2-8°C
- Compatible with Thrombin Time on an analyzer

**Go-DOAC™** Test reagent is a modified phospholipid-rich Russells viper venom reagent with enhanced sensitivity to DOACs. Go-DOAC™ is resistant to most lupus inhibitors and heparins (up to 1u/ml) but is sensitive to warfarin and defects in the common coagulation pathway. New or direct oral anticoagulants (DOACs) include inhibitors of thrombin (eg. dabigatran) and factor Xa (eg. rivaroxaban, apixaban and edoxaban). The latter group are difficult to quantitate using current clotting methods and expensive chromogenic assays for the individual agents are in use.

The lupus anticoagulant-resistant dilute Russells viper venom test (dRVV-LR or "Confirm") has been suggested as a possible test method for all the DOACs since it is very sensitive to both classes of these inhibitors in vitro and ex vivo (2) and is not affected by extraneous variables such as heparins, or low factor VIII, IX or XI levels than other clotting tests.



PRODUCT	REF	SIZE	STATUS
Go-DOAC™	X9211-FD	makes 4ml	RUO

### REFERENCES:

1. Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis or both? *Thromb. Haemost.* 2012; 107: 803-805.
2. Exner T, Ellwood L, Rubie J, Barancewicz A. Testing for new oral anticoagulants with LA resistant Russells viper venom reagents. An in vitro study. *Thromb. Haemost.* 2013; 109: 762-5.
3. Altman R, Gonzalez CD. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. *Thromb. J.* 2014; 12: 7.
4. Sennesael AL, Exner T, Chatelain B, et al. An optimized dRVV-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. *Thromb Res.* 2017; 157: 29-37.
5. Exner T, Michalopoulos N, Pearce J. et al. Simple method for removing DOACs from plasma samples. *Throm.Res.* 2018; 16:1028-39.

For research use only. Not for use in diagnostic procedures.

ML-00-01280 Rev01



---

Dr Thomas Exner founded Haematex in 2004, his motivation was to increase coagulation lab efficiency by improving and innovating diagnostic reagents. Haematex products are designed, manufactured and distributed under the highest standard of quality and safety.

---

**“Thrombosis and haemorrhage affect many clinical decisions, their control can impact treatment outcomes and indeed - life itself.”**

- Dr Thomas Exner



Suite 9/17 King Rd,  
Hornsby 2077 NSW  
Australia



[www.haematex.com](http://www.haematex.com)

For research use only. Not for use in diagnostic procedures.

ML-00-01280 Rev01

Email: [info@haematex.com](mailto:info@haematex.com)

Phone: (+61) 2 9482 2288